BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $10,820.50 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 425 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total transaction of $10,820.50. Following the completion of the sale, the executive vice president now directly owns 262,198 shares of the company’s stock, valued at approximately $6,675,561.08. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

BioLife Solutions Stock Up 5.7 %

Shares of NASDAQ BLFS opened at $26.25 on Thursday. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The company has a market capitalization of $1.22 billion, a PE ratio of -24.76 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm’s 50-day moving average is $26.67 and its two-hundred day moving average is $25.48.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. Equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Trading of BioLife Solutions

Institutional investors and hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC purchased a new position in shares of BioLife Solutions during the fourth quarter valued at approximately $26,000. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions in the third quarter worth $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions in the fourth quarter worth $31,000. Quest Partners LLC acquired a new stake in shares of BioLife Solutions in the third quarter worth $57,000. Finally, 1620 Investment Advisors Inc. increased its position in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 675 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. KeyCorp lifted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Northland Securities lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. Benchmark restated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Craig Hallum boosted their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.